Early Emergency Department Experience with 7-day Extended-Release Injectable Buprenorphine for Opioid Use Disorder

We report our early experiences with this medication, (investigational drug CAM2038) in the context of an ongoing clinical trial entitled, Emergency Department-Initiated BUP VAlidaTION (ED INNOVATION), to inform emergency clinicians as they consider incorporating this medication into their practice. The medication was approved by the European Medicines Agency in 2018 and the U.S. Food and Drug Administration in 2023 for those 18 years or older for the treatment of moderate to severe opioid use disorder (OUD). We report our experience with approximately 800 ED patients with opioid use disorder (OUD) who received the 7-day XR-BUP preparation in the ED between 6/2020-7/2023.PMID:37501652 | DOI:10.1111/acem.14782

Source: Accident and Emergency Nursing - July 28, 2023 Category: Emergency Medicine Authors: Gail D'Onofrio Jeanmarie Perrone Kathryn F Hawk Ethan Cowan Ryan McCormack Edouard Coupet Patricia H Owens Shara H Martel Kristen Huntley Sharon L Walsh Michelle R Lofwall Andrew Herring ED-INNOVATION Investigators Source Type: research